目的 探讨110例2型糖尿病患者肾小球滤过率(glomerular filtration rate,GFR)及尿白蛋白浓度(urine albumin concentration,UAC)情况,对2型糖尿病肾功能评价的价值。方法 对110例于内分泌科住院治疗的2型糖尿病患者测定晨尿微量白蛋白浓度,行肾动态显像检查,收集患者的一般临床资料。评价UAC及GFR值对患者肾功能的诊断价值及关联性。结果 UAC值与GFR值存在负相关性(P<0.05);当GFR值<60 ml/(min·1.73 m2)时,以GFR值为状态变量,UAC值为检验变量绘制ROC曲线发现,敏感度和特异度最佳截断点UAC值为10.90 mg/L。当患者GFR≥60 ml/(min·1.73 m2)时,UAC异常人群高血压发病率高于UAC正常人群(P<0.05)。结论 在2型糖尿病患者中,GFR值随UAC值的升高而降低,即UAC值在一定程度上能够反映出患者肾功能变化情况,但部分患者在GFR值明显下降[GFR<60 ml/(min·1.73 m2)]时,UAC仍可处于正常水平,此时评价2型糖尿病患者的肾功能情况不应该以传统标准(UAC<30 mg/L)为界限。在临床工作中需同时关注2型糖尿病患者,尤其是有高血压病史的老年患者的肾小球滤过率及尿蛋白情况,以免漏诊。
Abstract
Objective Through the analysis of glomerular filtration rate (GFR) and urinary albumin concentration (UAC) in 110 patients with type 2 diabetes, to discuss whether there is relevance between GFR and UAC in patients with type 2 diabetes and its application value. Methods One hundred and ten patients with type 2 diabetes were enrolled in this study. All of the patients received measurement of morning urine trace albumin concentration, and renal dynamic imaging examination. General clinical data were collected. Results UAC value was negatively related to GFR value(P<0.05).When GFR<60 ml/(min·1.73 m2), with GFR value as the gold standard, ROC curves showed that the optimal UAC value cut-off values were 10.90 mg/L by maximizing the sum of sensitivity and specificity. In GFR≥60 ml/(min·1.73 m2)group,the incidence of hypertension in patients with normal UAC value was higher than that in UAC abnormal patients(P<0.05). Conclusions In patients with type 2 diabetes, by the rise of UAC value,GFR value would come down. To some extent, UAC value can reflect the renal function changes in patients,but the evaluation of renal function in patients with type 2 diabetes should not be based on the traditional standard (UAC<30 mg/L)as the boundary, in some patients GFR value decreased obviously [GFR < 60 ml/(min·1.73 m2)] wheras UAC value can still be in a normal level. We need to focus on albuminuria and glomerular filtration rate at the same time in the clinical work in patients with type 2 diabetes especially in elderly patients with a history of high blood pressure in order to avoid misdiagnosis or missed diagnosis.
关键词
尿白蛋白浓度 /
肾小球滤过率 /
2型糖尿病 /
糖尿病肾脏疾病
Key words
urinary albumin concentration /
glomerular filtration rate /
type 2 diabetes /
diabetic kidney disease
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1]Collins A J, Foley RN, Chavers B, et al. 'United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States[J]. Am J Kidney Dis, 2012,59(1 Suppl 1):A7, e1-420.
[2] Mogensen C E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes[J]. N Engl J Med, 1984,310(6):356-360.
[3] K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification[J]. Am J Kidney Dis, 2002,39(2 Suppl 1):S1-266.
[4] Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?[J]. Diabet Med, 2008,25 Suppl 2:25-29.
[5] de Boer I H, Rue T C, Cleary P A, et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort[J]. Arch Intern Med, 2011,171(5):412-420.
[6] Derhaschnig U, Kittler H, Woisetschlager C, et al. Microalbumin measurement alone or calculation of the albumin/creatinine ratio for the screening of hypertension patients?[J]. Nephrol Dial Transplant, 2002,17(1):81-85.
[7] 沈玉美, 顾明君, 邹俊杰, 等. 随机尿微量白蛋白检测对筛检早期糖尿病肾病的价值[J]. 标记免疫分析与临床, 2002,(02):99-101.
[8] 郑林峰, 唐文彬, 陈立平. 微小RNA在糖尿病肾病发病机制及治疗中的研究进展[J]. 临床与病理杂志, 2014,(04):435-439.
[9] 李俊燕, 谭英姿, 冯国鄞, 等. 糖尿病肾病遗传学研究进展[J]. 遗传, 2012,(12):1537-1544.
[10] Yamagishi S, Matsui T. Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy[J]. Curr Pharm Biotechnol, 2011,12(3):362-368.
[11] 李 竞,毛拓华.糖尿病微血管病变[J]. 微循环学杂志,2013,23(2):1-4.
[12] de Zeeuw D, Parving H H, Henning R H. Microalbuminuria as an early marker for cardiovascular disease[J]. J Am Soc Nephrol, 2006,17(8):2100-2105.
[13] Thomas M C. Anemia in diabetes: marker or mediator of microvascular disease?[J]. Nat Clin Pract Nephrol, 2007,3(1):20-30.
[14] Ekundayo O J, Muchimba M, Aban I B, et al. Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure[J]. Am J Cardiol, 2009,103(1):88-92.
[15] So W Y, Kong A P, Ma R C, et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients[J]. Diabetes Care, 2006,29(9):2046-2052.
[16] McCullough P A, Li S, Jurkovitz C T, et al. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality[J]. Am Heart J, 2008,156(2):277-283.
[17] Thomas M C, Macisaac R J, Jerums G, et al. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON]11)[J]. Diabetes Care, 2009,32(8):1497-1502.
[18] Yokoyama H, Sone H, Oishi M, et al. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15)[J]. Nephrol Dial Transplant, 2009,24(4):1212-1219.
[19] Ohta M, Babazono T, Uchigata Y, et al. Comparison of the prevalence of chronic kidney disease in Japanese patients with Type 1 and Type 2 diabetes[J].Diabet Med, 2010,27(9):1017-1023.
[20] Macisaac RJ, Jerums G. Albuminuric and non-albuminuric pathways to renal impairment in diabetes[J].Minerva Endocrinol, 2005,30(3):161-177.
PDF(644 KB)
